John Wiener, MD
Urology · Durham, NCNPI 1407892748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $183 and has fallen 91.7% since, to $15 in 2024. That places this record below the midpoint for urology clinicians in NC, where the typical reported total is $2,562.
Across 6 payments — averaging $39.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$160
- Palette Life Sciences, Inc.$43
- C. R. Bard, Inc. & Subsidiaries$33
Across 23 payments — averaging $4883.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$87K
- Astellas Pharma Global Development$25K
What the payments were for
- Food & beverage$236100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $160 |
| Palette Life Sciences, Inc. | 2 | $43 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$129
How this compares
$236 in reported general payments places this provider in the 10th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 21 | $9,887 |
| Oxybutynin Chloride | 13 | $869 |
| Oxybutynin Chloride ErOxybutynin Chloride | 39 | $649 |
| Potassium Citrate ErPotassium Citrate | 12 | $466 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $429 |
| Lactulose | 13 | $400 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $353 |
Paid to pharmacies, not to this prescriber.
Other urology in Durham
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Jay KimDurham$202K
- Andrew PetersonDurham$124K
- Cary RobertsonDurham$76K
- Brant InmanDurham$55K
- Thomas PolascikDurham$54K
- Robert MedairosDurham$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.